Login
Companies $VTVT
$17.69 -$2.00 (10.16%) Live
vTv Therapeutics Inc. logo

vTv Therapeutics Inc.

Compare classes
vtvtherapeutics.com

What Do They Do?

Develops oral therapies for diabetes and other metabolic and inflammatory diseases, including cadisegliatin as an add-on to insulin for people with diabetes.

Who Are Their Customers?

Pharmaceutical partners license drug candidates and may collaborate on their development; academic partners also work with the company on research and development.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −34% (Loss)
vs −$8.7M in Q3 FY2025

Broader cadisegliatin trials The latest report describes an ongoing cadisegliatin trial for diabetes and adds a separate study in insulin-dependent people with diabetes; the older report described pivotal studies as planned.

Who Do They Compete With?

Competes with Zucara Therapeutics, Diasome Pharmaceuticals, Lexicon Pharmaceuticals, Adocia, Sanofi, Vertex Pharmaceuticals, and Eli Lilly

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support